"The data of a number of scientific studies carried out both in our country and abroad indicate that the preexisting immunity to adenoviruses practically does not affect the development of the immune response after immunization with vaccines based on adenovirus vectors," TASS cites his statement.
According to Gunzburg, experts have proven the possibility of re-vaccination with adenoviral vectors without loss of immunogenicity to the target antigen.
“Thus, revaccination with Sputnik V is not only possible, but may be even more effective than primary vaccination,” he added.
The center of Gamaleya also stated that "statements about the impossibility or undesirability of revaccination with the Sputnik V vaccine have no scientific basis and are misinformation."
“It is important to note that Rospotrebnadzor promptly issued a clarification on this score, correcting an extremely incorrect statement by a representative of the Central Research Institute of Epidemiology.
Our studies have shown that revaccination with Sputnik is not only possible, but may even be more effective than primary vaccination.
Revaccination results in a high immune response, and immunity to the human adenovirus-based vector cannot be a limiting factor, ”the report says.
On March 22, Russian President Vladimir Putin said that 6.3 million Russians have already been vaccinated against COVID-19 with one component, of which 4.3 million people have gone through the entire process.